Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus

Trial Profile

Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2017

At a glance

  • Drugs HB 101 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; First in man
  • Sponsors Hookipa Biotech
  • Most Recent Events

    • 04 May 2017 Results from this trial published in a Hookipa Biotech Media Release.
    • 04 May 2017 According to a Hookipa Biotech media release,data from this trial were reviewed by by an independent data and safety monitoring board.
    • 04 May 2017 According to a Hookipa Biotech media release, follow-up safety and immunogenicity results through month 12 from this study are expected in November 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top